Form 4: TScan Therapeutics Director Keith Woods Granted 67,000 Stock Options

TScan Therapeutics, Inc. Director Keith Woods was granted 67,000 stock options with an exercise price of $1.45, vesting fully by June 30, 2026, or the next annual meeting.

Summary

• Director Keith Woods of TScan Therapeutics, Inc. (TCRX) was granted 67,000 stock options on June 30, 2025.
• The stock options have an exercise price of $1.45 per share.
• The options are set to expire on June 30, 2035.
• The shares subject to these options will vest and become exercisable in full upon the earlier of June 30, 2026, or the next annual meeting of the Issuer's stockholders, contingent on Mr. Woods' continued service.
• Following this transaction, Keith Woods directly beneficially owns 67,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholders and incentivizes long-term performance, though it's a routine compensation mechanism rather than a significant operational or financial announcement.

Positives

• The grant of 67,000 stock options to Director Keith Woods aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• The exercise price of $1.45 suggests a potential belief in future stock price appreciation above this level by the company.

Negatives

• No immediate negative financial implications are apparent from this stock option grant, as it represents a form of equity compensation rather than a sale or dilution event.

Risks

• The value of the granted options is contingent on TScan Therapeutics' stock price appreciating above the exercise price of $1.45.
• Vesting of the options is subject to the Reporting Person's continued service, meaning the options could be forfeited if service ceases before the vesting conditions are met.

Future Outlook

The stock options are designed to vest fully by June 30, 2026, or the next annual meeting, indicating a future-oriented incentive for the director's continued service and contribution to the company's performance and long-term value creation.

Management Comments

• No direct management comments or quotes are provided in this regulatory filing, which is a standard disclosure of insider transactions.

Industry Context

This Form 4 filing reflects a standard practice of equity compensation for directors in publicly traded companies, particularly in the biotechnology sector, to align leadership incentives with long-term shareholder value creation and retention.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The grant of 67,000 stock options to Director Keith Woods constitutes a related party transaction, as it involves compensation from the Issuer to a member of its board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The granted stock options are expected to vest fully upon the earlier of June 30, 2026, or the next annual meeting of the Issuer's stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

TScan Therapeutics, TCRX, Stock Option, Director, Equity Compensation, Insider Transaction, Form 4, Keith Woods